Summary of Key Points
Finnish smart ring company Oura plans to go public on NASDAQ in September, aiming to raise up to $3 billion and valuing itself at over $16 billion, which would be the largest IPO in the consumer wearable device sector in a decade. However, there are four critical issues underlying this listing: significant cashouts by existing shareholders (not due to pessimism, but a natural part of the capital cycle); doubts about the effectiveness of its core feature (sleep monitoring) amidst class-action lawsuits; questions as to whether its AI capabilities can support such a high valuation; and the competitive pressure from established players (Samsung, Apple) entering the market. Oura's valuation strategy is to transition from a hardware company to a SaaS (subscription service) business, but this transition is fraught with challenges. If the subscription business fails to meet expectations, the $16 billion valuation could face a "Davis Double Kill" – a simultaneous decline in both performance and valuation.
1. Existing Shareholders' Cashouts: Not Pessimism, but Capital Seeking Exit
Oura has raised a total of $1.5 billion, with investors such as Fidelity and ICONIQ contributing significantly. They are selling their shares now before the IPO. The reason is not a lack of confidence in the company, but rather the pressure from capital to recoup their investment (referred to in industry terms as DPI, or "Dollar for Dollar Return"). The company's valuation increased to $5.2 billion in the Series D round by the end of 2024 and to $1.1 billion in the Series E round by 2025, doubling in less than a year. It makes sense for them to sell their shares now. This is similar to selling stocks that have appreciated significantly; after all, their funds come from LPs (limited partners), and they need to report their performance to them. These cashouts are a normal part of the capital cycle and do not indicate that the company is on the decline.
2. Class-Action Lawsuits Highlighting Issues
Oura is facing two critical class-action lawsuits:
- Automatic Renewal Issues: Users argue that they were not informed about the automatic subscription fee when purchasing the ring, and canceling the subscription is cumbersome, which violates California law. Subscription-based models are crucial for Oura's transition to a SaaS business, so any compliance issues could impact its valuation.
- Sleep Monitoring Accuracy: Users accuse the company of misleading consumers, claiming that the sleep monitoring accuracy is merely around 53%. It's important to clarify that Oura's claimed 95% accuracy refers to the ability to distinguish between sleeping and awake states, while the lawsuit's 53% accuracy refers to the ability to differentiate between light sleep, deep sleep, and REM (Rapid Eye Movement) stages. The gold standard in medical sleep monitoring is electroencephalogram (EEG) tests, but Oura's ring relies on peripheral signals like heart rate and body temperature to estimate sleep patterns, which is a technical limitation in the industry. The debate is not about the accuracy of the data itself, but whether Oura's marketing claims (e.g., calling it a "medical-grade device") are exaggerated. If the company markets the product as a professional medical tool when it is merely a consumer-grade product, it may be considered misleading.
3. The Mystery Behind the $16 Billion Valuation
Although 80% of Oura's revenue comes from selling the ring (hardware), the capital market is valuing it like a SaaS company (e.g., Microsoft or Salesforce). The overall valuation of $16 billion corresponds to a 16x price-to-sales ratio based on 2025 revenue. However, if only the subscription revenue ($144 million) is considered, the ratio exceeds 110x. This is because hardware sales are a one-time transaction, while subscriptions generate recurring revenue, which the market values more highly. The risk is that if subscription growth slows or the renewal rate declines, the valuation could plummet due to a "Davis Double Kill."
4. Can AI Support the High Valuation?
AI was a key factor in raising the valuation from $1.1 billion to $1.6 billion, with the introduction of the Oura Advisor AI health assistant in 2024. However, this AI currently merely summarizes sleep and heart rate data into text (e.g., "You had less deep sleep last night; it's recommended to go to bed earlier"). It lacks the ability to provide medical diagnoses or generate additional revenue. In essence, it's just a new way of presenting existing data, not a true "AI revolution." More importantly, doctors often disregard such data; if a patient presents with an Oura sleep report, they will likely recommend a professional sleep monitoring test. Therefore, whether the AI feature can support the high valuation remains uncertain.
5. Competitive Pressure from Giants
Oura currently holds 74% of the global smart ring market share, but giants like Samsung (with the Galaxy Ring) and Apple ( rumored to be developing a smart ring led by their health division) are entering the market. Domestic competitors like RingConn are appealing to consumers with no subscription fee and competitive pricing. Oura is also engaged in patent disputes with Samsung. However, it has its own advantages:
- B2B Business: It has partnerships with the U.S. Department of Defense and has acquired a corporate health company, which, although not publicly disclosed, supports its narrative of being a data platform provider.
- Brand Recognition: The ring has been worn by high-profile individuals like Prince Harry and Eileen Gu, reinforcing its image as a high-end, professional health tool and helping it maintain a price point above $300 (while domestic competitors focus on lower-priced options).
With the entry of these giants, the market will become more competitive. Apple has an ecosystem advantage (integration with iPhone and Apple Watch), and Samsung has supply chain advantages. How long Oura can maintain its lead is uncertain, making this the biggest unknown factor in its IPO.
6. The IPO as a Gamble
The $16 billion valuation is a gamble on two outcomes: whether Oura can successfully transition from a hardware company to a SaaS subscription platform and whether it can establish a significant market for smart rings before Samsung and Apple enter. If successful, it could become a niche, high-end brand. Otherwise, it may be marginalized by the giants. The $3 billion in funds raised is a "time window" to achieve this transition. Whether it can turn this window into a competitive advantage depends on its subscription growth and technological breakthroughs. The outcome of this IPO will also set a precedent for other health hardware companies: how far can they go with peripheral data (from fingers and wrists) to replicate medical precision? The answer lies in Oura's IPO.